At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
HCWB HCW Biologics Inc.
Post-Mkt 03-02 17:10:02 EST
0.5500
+0.0094
+1.74%
盘后0.5400
-0.0100-1.82%
16:54 EST
High0.5500Low0.4859Vol59.85K
Open0.5306D1 Closing0.5406Amplitude11.86%
Mkt Cap3.17MTradable Cap1.33MTotal Shares5.76M
T/O31.53KT/O Rate2.47%Tradable Shares2.42M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

HCW Biologics regains compliance with continued listing rules for Nasdaq
TIPRANKS  ·  03-02 21:38
HCW Biologics regains compliance with continued listing rules for Nasdaq
HCW Biologics Regains Nasdaq Listing Compliance, Faces Ongoing Oversight
TIPRANKS  ·  03-02 21:34
HCW Biologics Regains Nasdaq Listing Compliance, Faces Ongoing Oversight
BRIEF-HCW Biologics Regains Compliance With All Continued Listing Rules For Nasdaq Per Nasdaq Determination Letter
Reuters  ·  03-02 21:29
BRIEF-HCW Biologics Regains Compliance With All Continued Listing Rules For Nasdaq Per Nasdaq Determination Letter
Nasdaq Panel Restores HCW Biologics’ Listing Compliance
Reuters  ·  03-02 21:01
Nasdaq Panel Restores HCW Biologics’ Listing Compliance
HCW Biologics Prices $1.5 Million Offering With Warrants at $0.6055 Per Share
Reuters  ·  02-18
HCW Biologics Prices $1.5 Million Offering With Warrants at $0.6055 Per Share
HCW Biologics Announces Pricing of $1.5 Million Follow-on Offering Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  02-18
HCW Biologics Announces Pricing of $1.5 Million Follow-on Offering Priced at-the-Market Under Nasdaq Rules
Press Release: HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Dow Jones  ·  02-18
Press Release: HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
HCW Biologics Licenses TRBC Asset to China JV Trimmune
TIPRANKS  ·  02-13
HCW Biologics Licenses TRBC Asset to China JV Trimmune
HCW Biologics, WY Biotech close first round of financing for joint venture
TIPRANKS  ·  02-13
HCW Biologics, WY Biotech close first round of financing for joint venture
HCW Biologics and Wy Biotech Announce Closing of First Round of Financing for Newly Formed Joint Venture Trimmune
THOMSON REUTERS  ·  02-13
HCW Biologics and Wy Biotech Announce Closing of First Round of Financing for Newly Formed Joint Venture Trimmune
Press Release: HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
Dow Jones  ·  02-13
Press Release: HCW Biologics and WY Biotech Announce Closing of First Round of Financing For Newly Formed Joint Venture Trimmune
HCW Biologics files to sell 9.52M shares of common stock, warrants
TIPRANKS  ·  02-12
HCW Biologics files to sell 9.52M shares of common stock, warrants
HCW Biologics files to sell 3.4M shares of common stock for holders
TIPRANKS  ·  01-10
HCW Biologics files to sell 3.4M shares of common stock for holders
HCW Biologics Raises $3.8 Million Through Warrant Exercise and Equity Issuance
Reuters  ·  01-01
HCW Biologics Raises $3.8 Million Through Warrant Exercise and Equity Issuance
HCW Biologics Secures $4M Through Warrant Exercise
TIPRANKS  ·  2025-11-21
HCW Biologics Secures $4M Through Warrant Exercise
HCW Biologics Raises $4 Million Through Private Placement of Unregistered Warrants
Reuters  ·  2025-11-21
HCW Biologics Raises $4 Million Through Private Placement of Unregistered Warrants
BRIEF-Hcw Biologics Announces Warrant Inducement Agreement
Reuters  ·  2025-11-19
BRIEF-Hcw Biologics Announces Warrant Inducement Agreement
HCW Biologics Inc - Announces Warrant Inducement Agreement
THOMSON REUTERS  ·  2025-11-19
HCW Biologics Inc - Announces Warrant Inducement Agreement
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
GlobeNewswire  ·  2025-11-19
HCW Biologics Enters into $4.0 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease
GlobeNewswire  ·  2025-11-18
HCW Biologics Announces Initiation of First-In-Human Clinical Trial to Evaluate HCW9302 in an Autoimmune Disease

Introduction

Company Name.
HCW Biologics Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Issue price:
--